Optimisation of imipenem regimens in patients with impaired renal function by pharmacokinetic-pharmacodynamic target attainment analysis of plasma and urinary concentration data

International Journal of Antimicrobial Agents

Volumn 40, Issue 5, 2012, Pages 427-433

  Yoshizawa, Kenichi ^a   Ikawa, Kazuro ^a   Ikeda, Kayo ^a   Kumon, Hiromi ^b   Ohge, Hiroki ^c   Morikawa, Norifumi ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Breakpoint; Carbapenem; Creatinine clearance; Probability of target attainment

Indexed keywords

IMIPENEM;

ADULT; AGED; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG URINE LEVEL; ESCHERICHIA COLI; FEMALE; HAEMOPHILUS INFLUENZAE; HUMAN; KIDNEY DYSFUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROBABILITY; PROBABILITY OF TARGET ATTAINMENT; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; FEMALE; HUMANS; IMIPENEM; INFUSIONS, INTRAVENOUS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLASMA; RENAL INSUFFICIENCY; TIME FACTORS; URINE;

EID: 84867396363     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.06.011     Document Type: Article

References (25)

1. M. Dreetz, J. Hamacher, J. Eller, K. Borner, P. Koeppe, and T. Schaberg Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin Antimicrob Agents Chemother 40 1996 105 109
2. S.R. Norrby, K. Alestig, B. Björnegård, L.A. Burman, F. Ferber, and J.L. Huber Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors Antimicrob Agents Chemother 23 1983 300 307
3. U. Flückiger, C. Segessenmann, and A.U. Gerber Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model Antimicrob Agents Chemother 35 1991 1905 1910
4. A.D. Miller, A.M. Ball, P.B. Bookstaver, E.K. Dornblaser, and C.L. Bennett Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations Pharmacotherapy 31 2011 408 423
5. M. Fujimoto, M. Munakata, and N. Akaike Dual mechanisms of GABAA response inhibition by beta-lactam antibiotics in the pyramidal neurones of the rat cerebral cortex Br J Pharmacol 116 1995 3014 3020
6. M. Sunagawa, H. Matsumura, Y. Sumita, and H. Nouda Structural features resulting in convulsive activity of carbapenem compounds: effect of C-2 side chain J Antibiot (Tokyo) 48 1995 408 416
7. B.S. Koppel, W.A. Hauser, C. Politis, D. van Duin, and M. Daras Seizures in the critically ill: the role of imipenem Epilepsia 42 2001 1590 1593
8. D.J. Winston, W.G. Ho, D.A. Bruckner, R.P. Gale, and R.E. Champlin Controlled trials of double β-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients Am J Med 85 1988 21 30
9. G. Calandra, E. Lydick, J. Carrigan, L. Weiss, and H. Guess Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin Am J Med 84 1988 911 918
10. K. Ikawa, N. Morikawa, K. Sakamoto, K. Ikeda, H. Ohge, and Y. Takesue Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients Chemotherapy 54 2008 131 139
11. K. Ikawa, N. Morikawa, K. Ikeda, H. Ohge, and T. Sueda Development of breakpoints of carbapenems for intraabdominal infections based on pharmacokinetics and pharmacodynamics in peritoneal fluid J Infect Chemother 14 2008 330 332
12. European Committee on Antimicrobial Susceptibility Testing (EUCAST). MIC distributions. http://www.eucast.org/mic-distributions/ [accessed 18.02.12].
13. J.W. Mouton, M.N. Dudley, O. Cars, H. Derendorf, and G.L. Drusano Standardization of pharmacokinetic-pharmacodynamic (PK-PD) terminology for anti-infective drugs: an update J Antimicrob Chemother 55 2005 601 607
14. G.A. Verpooten, L. Verbist, A.P. Buntinx, L.A. Entwistle, K.H. Jones, and M.E. De Broe The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure Br J Clin Pharmacol 18 1984 183 193
15. M. Fukasawa, Y. Sumita, E.T. Harabe, T. Tanio, H. Nouda, and T. Kohzuki Stability of meropenem and effect of 1 β-methyl substitution on its stability in the presence of renal dehydropeptidase I Antimicrob Agents Chemother 36 1992 1577 1579
16. E. Dailly, M.F. Kergueris, M. Pannier, P. Jolliet, and M. Bourin Population pharmacokinetics of imipenem in burn patients Fundam Clin Pharmacol 17 2003 645 650
17. F. Lamoth, T. Buclin, C. Csajka, A. Pascual, T. Calandra, and O. Marchetti Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies Antimicrob Agents Chemother 53 2009 785 787
18. S.G. Sakka, A.K. Glauner, J.B. Bulitta, M. Kinzig-Schippers, W. Pfister, and G.L. Drusano Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial Antimicrob Agents Chemother 51 2007 3304 3310
19. L.S. Lee, M. Kinzig-Schippers, A.N. Nafziger, L. Ma, F. Sörgel, and R.N. Jones Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation Diagn Microbiol Infect Dis 68 2010 251 258
20. S. Jaruratanasirikul, and T. Sudsai Comparison of the pharmacodynamics of imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5 h infusion J Antimicrob Chemother 63 2009 560 563
21. M. Campise Neurological complication during imipenem/cilastatin therapy in uraemic patients Nephrol Dial Transplant 13 1998 1895 1896
22. M. Horiuchi, M. Kimura, M. Tokumura, N. Hasebe, T. Arai, and K. Abe Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics Toxicology 222 2006 114 124
23. A. Dupuis, W. Couet, J. Paquereau, S. Debarre, A. Portron, and C. Jamois Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats Antimicrob Agents Chemother 45 2001 1682 1687
24. S.R. Norrby, J.D. Rogers, F. Ferber, K.H. Jones, A.G. Zacchei, and L.L. Weidner Disposition of radiolabeled imipenem and cilastatin in normal human volunteers Antimicrob Agents Chemother 26 1984 707 714
25. C. Dahyot-Fizelier, S. Lefeuvre, L. Laksiri, S. Marchand, R.J. Sawchuk, and W. Couet Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis Clin Pharmacokinet 49 2010 323 334